For-profit healthcare in the news

Legion Troll

A fine upstanding poster
565638781b0000470029ea6d.jpeg


Turing’s CEO, former hedge fund manager Martin Shkreli


Turing Pharmaceuticals is reneging on its promise to cut the cost of the lifesaving drug Daraprim, after buying the rights to the drug and raising the price fiftyfold from $13.50 to $750 per per pill.

“A drug’s list price is not the primary factor in determining patient affordability and access,” Nancy Retzlaff, Turing’s chief commercial officer, said. “A reduction in Daraprim’s list price would not translate into a benefit to patients.”

The 62-year-old drug had no competition until a furor over the gigantic price hike erupted, triggering multiple government investigations.

A pharmacy that compounds prescription drugs for individual patients then stepped in and started selling a capsule version for 99 cents. Imprimis Pharmaceuticals says orders are pouring in from doctors and that it has dispensed more than 2,500 capsules in barely a month.




http://www.huffingtonpost.com/entry/turing-price-daraprim_565633c6e4b079b2818a31bc
 
Back
Top